Clinical Laboratory Improvement Advisory Committee, 48930 [E6-13828]

Download as PDF cprice-sewell on PROD1PC66 with NOTICES 48930 Federal Register / Vol. 71, No. 162 / Tuesday, August 22, 2006 / Notices 225), and all other applicable statutes and regulations to become a bank holding company and/or to acquire the assets or the ownership of, control of, or the power to vote shares of a bank or bank holding company and all of the banks and nonbanking companies owned by the bank holding company, including the companies listed below. The applications listed below, as well as other related filings required by the Board, are available for immediate inspection at the Federal Reserve Bank indicated. The application also will be available for inspection at the offices of the Board of Governors. Interested persons may express their views in writing on the standards enumerated in the BHC Act (12 U.S.C. 1842(c)). If the proposal also involves the acquisition of a nonbanking company, the review also includes whether the acquisition of the nonbanking company complies with the standards in section 4 of the BHC Act (12 U.S.C. 1843). Unless otherwise noted, nonbanking activities will be conducted throughout the United States. Additional information on all bank holding companies may be obtained from the National Information Center website at www.ffiec.gov/nic/. Unless otherwise noted, comments regarding each of these applications must be received at the Reserve Bank indicated or the offices of the Board of Governors not later than September 15, 2006. A. Federal Reserve Bank of Chicago (Patrick M. Wilder, Assistant Vice President) 230 South LaSalle Street, Chicago, Illinois 60690-1414: 1. Lincoln Bancorp, Plainfield, Indiana; to become a bank holding company upon the conversion of Lincoln Bank, Plainfield, Indiana, from a federal savings bank to a state– chartered commercial bank. B. Federal Reserve Bank of Dallas (W. Arthur Tribble, Vice President) 2200 North Pearl Street, Dallas, Texas 752012272: 2. Industry Bancshares, Inc., Industry, Texas, and Industry Holdings, Inc., Wilmington, Delaware; to acquire 100 percent of the voting shares of Community Bancorporation, Inc., Bellville, Texas, and thereby indirectly acquire Bellville Holdings, Inc., Wilmington, Delaware, and First National Bank of Bellville, Bellville, Texas. Board of Governors of the Federal Reserve System, August 17, 2006. Robert deV. Frierson, Deputy Secretary of the Board. [FR Doc. E6–13832 Filed 8–21–06; 8:45 am] BILLING CODE 6210–01–S VerDate Aug<31>2005 15:34 Aug 21, 2006 Jkt 208001 DEPARTMENT OF HEALTH AND HUMAN SERVICES Centers for Disease Control and Prevention Clinical Laboratory Improvement Advisory Committee In accordance with section 10(a)(2) of the Federal Advisory Committee Act (P.L. 92–463), the Centers for Disease Control and Prevention (CDC) announces the following committee meeting. Name: Clinical Laboratory Improvement Advisory Committee (CLIAC). Times and Dates: 8:30 a.m.–5 p.m., September 20, 2006. 8:30 a.m.–3 p.m., September 21, 2006. Place: Sheraton Midtown Atlanta Hotel at Colony Square, 188 14th Street, NE., Atlanta, Georgia 30361, Telephone: (404) 892–6000. Status: Open to the public, limited only by the space available. The meeting room accommodates approximately 100 people. Purpose: This Committee is charged with providing scientific and technical advice and guidance to the Secretary of Health and Human Services, the Assistant Secretary for Health, and the Director, CDC, regarding the need for, and the nature of, revisions to the standards under which clinical laboratories are regulated; the impact on medical and laboratory practice of proposed revisions to the standards; and the modification of the standards to accommodate technological advances. Matters To Be Discussed: The agenda will include updates from the CDC, the Centers for Medicare & Medicaid Services, and the Food and Drug Administration; and presentations and discussion concerning the future of health laboratory practice including future directions in laboratory technology, interfaces between the laboratory and clinicians, and the future of the laboratory workforce. Agenda items are subject to change as priorities dictate. Providing Oral or Written Comments: It is the policy of CLIAC to accept written public comments and provide a brief period for oral public comments whenever possible. Oral Comments: In general, each individual or group requesting to make an oral presentation will be limited to a total time of five minutes (unless otherwise indicated). Speakers must also submit their comments in writing for inclusion in the meeting’s Summary Report. To assure adequate time is scheduled for public comments, individuals or groups PO 00000 Frm 00024 Fmt 4703 Sfmt 4703 planning to make an oral presentation should, when possible, notify the contact person below at least one week prior to the meeting date. Written Comments: For individuals or groups unable to attend the meeting, CLIAC accepts written comments until the date of the meeting (unless otherwise stated). However, the comments should be received at least one week prior to the meeting date so that the comments may be made available to the Committee for their consideration and public distribution. Written comments, one hard copy with original signature, should be provided to the contact person below. Written comments will be included in the meeting’s Summary Report. Contact Person for Additional Information: Devery Howerton, Acting Chief, Laboratory Practice Standards Branch, Division Public Health Partnerships—Laboratory Systems, National Center for Health Marketing, Coordinating Center for Health Information and Service, CDC, 1600 Clifton Road, NE., Mailstop G–23, Atlanta, Georgia 30333; telephone (404) 718–1016; fax (404) 718–1080; or via email at DHowerton@cdc.gov. The Director, Management Analysis and Services Office, has been delegated the authority to sign Federal Register Notices pertaining to announcements of meetings and other committee management activities, for CDC and the Agency for Toxic Substances and Disease Registry. Dated: August 15, 2006. Alvin Hall, Director, Management Analysis and Services Office, Centers for Disease Control and Prevention. [FR Doc. E6–13828 Filed 8–21–06; 8:45 am] BILLING CODE 4163–18–P DEPARTMENT OF HEALTH AND HUMAN SERVICES Food and Drug Administration Orthopaedic and Rehabilitation Devices Panel of the Medical Devices Advisory Committee; Notice of Meeting AGENCY: Food and Drug Administration, HHS. ACTION: Notice. This notice announces a forthcoming meeting of a public advisory committee of the Food and Drug Administration (FDA). At least one portion of the meeting will be closed to the public. Name of Committee: Orthopaedic and Rehabilitation Devices Panel of the Medical Devices Advisory Committee. E:\FR\FM\22AUN1.SGM 22AUN1

Agencies

[Federal Register Volume 71, Number 162 (Tuesday, August 22, 2006)]
[Notices]
[Page 48930]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: E6-13828]


=======================================================================
-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Centers for Disease Control and Prevention


Clinical Laboratory Improvement Advisory Committee

    In accordance with section 10(a)(2) of the Federal Advisory 
Committee Act (P.L. 92-463), the Centers for Disease Control and 
Prevention (CDC) announces the following committee meeting.
    Name: Clinical Laboratory Improvement Advisory Committee (CLIAC).
    Times and Dates: 8:30 a.m.-5 p.m., September 20, 2006. 8:30 a.m.-3 
p.m., September 21, 2006.
    Place: Sheraton Midtown Atlanta Hotel at Colony Square, 188 14th 
Street, NE., Atlanta, Georgia 30361, Telephone: (404) 892-6000.
    Status: Open to the public, limited only by the space available. 
The meeting room accommodates approximately 100 people.
    Purpose: This Committee is charged with providing scientific and 
technical advice and guidance to the Secretary of Health and Human 
Services, the Assistant Secretary for Health, and the Director, CDC, 
regarding the need for, and the nature of, revisions to the standards 
under which clinical laboratories are regulated; the impact on medical 
and laboratory practice of proposed revisions to the standards; and the 
modification of the standards to accommodate technological advances.
    Matters To Be Discussed: The agenda will include updates from the 
CDC, the Centers for Medicare & Medicaid Services, and the Food and 
Drug Administration; and presentations and discussion concerning the 
future of health laboratory practice including future directions in 
laboratory technology, interfaces between the laboratory and 
clinicians, and the future of the laboratory workforce. Agenda items 
are subject to change as priorities dictate.
    Providing Oral or Written Comments: It is the policy of CLIAC to 
accept written public comments and provide a brief period for oral 
public comments whenever possible. Oral Comments: In general, each 
individual or group requesting to make an oral presentation will be 
limited to a total time of five minutes (unless otherwise indicated). 
Speakers must also submit their comments in writing for inclusion in 
the meeting's Summary Report. To assure adequate time is scheduled for 
public comments, individuals or groups planning to make an oral 
presentation should, when possible, notify the contact person below at 
least one week prior to the meeting date. Written Comments: For 
individuals or groups unable to attend the meeting, CLIAC accepts 
written comments until the date of the meeting (unless otherwise 
stated). However, the comments should be received at least one week 
prior to the meeting date so that the comments may be made available to 
the Committee for their consideration and public distribution. Written 
comments, one hard copy with original signature, should be provided to 
the contact person below. Written comments will be included in the 
meeting's Summary Report.
    Contact Person for Additional Information: Devery Howerton, Acting 
Chief, Laboratory Practice Standards Branch, Division Public Health 
Partnerships--Laboratory Systems, National Center for Health Marketing, 
Coordinating Center for Health Information and Service, CDC, 1600 
Clifton Road, NE., Mailstop G-23, Atlanta, Georgia 30333; telephone 
(404) 718-1016; fax (404) 718-1080; or via e-mail at DHowerton@cdc.gov.
    The Director, Management Analysis and Services Office, has been 
delegated the authority to sign Federal Register Notices pertaining to 
announcements of meetings and other committee management activities, 
for CDC and the Agency for Toxic Substances and Disease Registry.

    Dated: August 15, 2006.
Alvin Hall,
Director, Management Analysis and Services Office, Centers for Disease 
Control and Prevention.
[FR Doc. E6-13828 Filed 8-21-06; 8:45 am]
BILLING CODE 4163-18-P

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.